GSK3B, glycogen synthase kinase 3 beta, 2932

N. diseases: 393; N. variants: 25
Disease: ovarian neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.040 Biomarker disease BEFREE Expression levels of multidrug resistance-associated protein 1 (<i>MRP1</i>), glutathione S-transferase π (<i>GST-π</i>) and glycogen synthase kinase-3β (<i>GSK3β</i>) were investigated in ovarian epithelial cancer and the relationship with the primary drug resistance of patients with ovarian cancer to chemotherapy. 31289467 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.040 Biomarker disease BEFREE All of the results demonstrated that compound 20g, as the first reported non-ATP competitive small molecule inhibitor of GSK 3β with suppression efficacy on ovarian cancer both in vitro and in vivo, might represent a potential candidate for the treatment of OC. 28460311 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.040 Biomarker disease BEFREE We wished to ascertain if the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime, known as "BIO," can suppress OC development. 26526575 2016
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.040 AlteredExpression disease LHGDN Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. 16788573 2006